Proteasome Inhibitor Based Therapy for Treatment of Newly Diagnosed Multiple Myeloma
Multiple myeloma is a hematologic malignancy that is unable to be cured and has significant impact throughout the world. Front line treatment has shifted but ultimately has landed on a bortezomib based, combination therapy. Carfilzomib is a next generation proteasome inhibitor shown to improve both progression free survival and overall survival in relapsed and refractory multiple myeloma in combination with lenalidomide and dexamethasone (KRd). Given the favorable response rates seen in phase II trials treating newly diagnosed myeloma, this combination is listed as a viable option for upfront treatment. (Source: Seminars in Oncology)
Source: Seminars in Oncology - January 12, 2018 Category: Cancer & Oncology Authors: Andrae Vandross Source Type: research
PD-1 Immunobiology in Autoimmune Hepatitis and Hepatocellular Carcinoma
Disruption of liver immune tolerance allows for the development of autoimmune hepatitis (AIH) and hepatocellular carcinoma (HCC). AIH rarely progresses to HCC but the diseases similarly induce the production of IL-18 and matrix metalloproteinases. These molecules have distinct effects on the immune response, including the programmed cell-death 1 (PD-1) axis. In this review, differences in PD-1 function and possible cell signals in AIH and HCC are highlighted. (Source: Seminars in Oncology)
Source: Seminars in Oncology - January 6, 2018 Category: Cancer & Oncology Authors: Colleen S. Curran, Elad Sharon Source Type: research
Liver PD-1 Immunobiology
Disruption of liver immune tolerance allows for the development autoimmune hepatitis (AIH) and hepatocellular carcinoma (HCC). AIH rarely progresses to HCC but the diseases similarly induce the production of IL-18 and matrix metalloproteinases. These molecules have distinct effects on the immune response, including the Programmed cell-death 1 (PD-1) axis. In this review, differences in PD-1 function and possible cell signals in AIH and HCC are highlighted. (Source: Seminars in Oncology)
Source: Seminars in Oncology - January 6, 2018 Category: Cancer & Oncology Authors: Colleen S. Curran, Elad Sharon Source Type: research
Mind the Graph. Foregone Health Gains in Lung Cancer
As thoracic medical oncologists treating patients with Anaplastic Lymphoma Kinase (ALK)-rearranged lung cancer in Australia and New Zealand, we read with interest the efforts of Evans et al [1] to benchmark funded cancer treatments between our two countries. The authors focussed on Progression Free Survival (PFS) and Overall Survival (OS) with application of ASCO-CRC targets and only included therapies with a comparator treatment available in New Zealand. We concur with the critique of methodology published in response by Zalcberg and Wonder [2] and would like to specifically address conclusions made in the setting of ALK-...
Source: Seminars in Oncology - December 2, 2017 Category: Cancer & Oncology Authors: Laird Cameron, Richard Sullivan, Brendan Luey, Ben Solomon Source Type: research
outside front cover
(Source: Seminars in Oncology)
Source: Seminars in Oncology - December 1, 2017 Category: Cancer & Oncology Source Type: research
Masthead
(Source: Seminars in Oncology)
Source: Seminars in Oncology - December 1, 2017 Category: Cancer & Oncology Source Type: research
Editorial Board
(Source: Seminars in Oncology)
Source: Seminars in Oncology - December 1, 2017 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Seminars in Oncology)
Source: Seminars in Oncology - December 1, 2017 Category: Cancer & Oncology Source Type: research
Leveraging Comparative Oncology in the Hopes of Improving Therapies for Breast Cancer
In the setting of cancer drug development, Comparative Oncology involves the inclusion of dogs with naturally occurring cancer in clinical trials of novel cancer drugs to answer questions that cannot be answered in the development of novel therapeutics using conventional animal models of cancer or human clinical trials alone [1]. The current conventional approach to oncology drug development is flawed and needs to be improved, with fewer than 3% of drugs that enter human trials advancing to human approval. (Source: Seminars in Oncology)
Source: Seminars in Oncology - November 22, 2017 Category: Cancer & Oncology Authors: Chand Khanna Tags: Discussion Source Type: research
Discussion on Raposo et al
In the setting of cancer drug development, Comparative Oncology involves the inclusion of dogs with naturally occurring cancer in clinical trials of novel cancer drugs to answer questions that cannot be answered in the development of novel therapeutics using conventional animal models of cancer or human clinical trials alone [1]. The current conventional approach to oncology drug development is flawed and needs to be improved, with fewer than 3% of drugs that enter human trials advancing to human approval. (Source: Seminars in Oncology)
Source: Seminars in Oncology - November 22, 2017 Category: Cancer & Oncology Authors: Chand Khanna Tags: Discussion Source Type: research
The Prodigious Network of Chromosome 17 miRNAs Regulating Cancer Genes that Influence the Hallmarks of Cancer
Chromosome 17 (Chr17) harbors crucial genes that encode proteins implicated in a variety of cancers including some that guard cancer cells from genomic instability and others that interfere with metastasis. Included amongst the genes on chr17 that regulate biological processes fundamental to the genesis of cancer are TP53, BRCA1, CCL5, NF-1, and GRB7. As many as 50% of all human tumors and at least 30% of breast carcinomas contain p53 mutations, while 30-40% of breast cancers have defective BRCA1. (Source: Seminars in Oncology)
Source: Seminars in Oncology - November 10, 2017 Category: Cancer & Oncology Authors: Sarada Achyutuni, Revathy Nadhan, Satheesh Kumar Sengodan, Priya Srinivas Source Type: research
Male Breast Cancer: Epidemiology and Risk Factors
Male breast cancer is a rare malignancy that accounts for less than1% of all cancers in men and less than 1% of all breast cancers. But the incidence is rising and in some patient groups reaching 15% over the course of their lives. The major risk factors for the development of male breast cancer include advancing age, hormonal imbalance, radiation exposure and a family history for breast cancer. Regarding the latter it can be linked to mutations in high or low penetrance genes. The most relevant risk factor for the development of male breast cancer is a mutation in the BRCA2 gene. (Source: Seminars in Oncology)
Source: Seminars in Oncology - November 9, 2017 Category: Cancer & Oncology Authors: Ali Jad Abdelwahab Yousef Source Type: research
LAMPs: Shedding Light on Cancer Biology
Lysosomes are important cytoplasmic organelles whose critical functions in cells are increasingly being understood. In particular, despite the long-standing accepted concept about the role of lysosomes as cellular machineries solely assigned to degradation, it has been demonstrated that they play active roles in homeostasis and even in cancer biology. Indeed, it is now well documented that during the process of cellular transformation and cancer progression lysosomes are changing localization, composition and volume and, through the release of their enzymes, lysosomes can also enhance cancer aggressiveness. (Source: Seminars in Oncology)
Source: Seminars in Oncology - November 4, 2017 Category: Cancer & Oncology Authors: Federica Alessandrini, Laura Pezz รจ, Yari Ciribilli Source Type: research
